Bulimia Nervosa Market Research Report Information by Disorder Type (Purging and Non-Purging), Drug Type (Antidepressants, Antipsychotics, and Others), Route of Administration (Oral, Intravenous, and Others), End User (Hospitals & Clinics, Homecare Settings, Specialty Centers, and Others), and Region (the Americas, Europe, Asia-Pacific, and the Middle East & Africa)—Forecast till 2032

Global Bulimia Nervosa Market Overview

Bulimia Nervosa Market Size was valued at USD 0.59 Billion in 2023. The Global Bulimia Nervosa industry is projected to grow from USD 0.63 Billion in 2024 to USD 1.02 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.30% during the forecast period (2024 - 2032). Bulimia nervosa is an eating disorder that is characterized by eating a large amount of food (binge eating) in a short period. The disorder is also known as bulimia. Bulimia nervosa may cause various life-threatening and serious complications, such as heart problems, tooth & gum decay, anxiety, self-injury, dehydration, and digestive problems. 

Factors such as the rising prevalence of psychological disorders, alcoholism, and diabetes are expected to drive market growth. According to an article published by the National Alliance on Mental Illness (NAMI), 19.1% adults in the US experienced mental illness in 2018. Moreover, drastically changing lifestyle is also expected to boost market growth. However, factors such as the lack of drugs specifically for the treatment of bulimia nervosa and lack of awareness regarding the treatment options are expected to hamper the market growth.   

Bulimia Nervosa Market Segmentation

The bulimia nervosa market has been segmented into disorder type, drug type, route of administration, end user, and region. Based on disorder type, the bulimia nervosa market has been divided into purging and non-purging. The bulimia nervosa market, by drug type, has been segmented into antidepressants, antipsychotics, and others. Based on route of administration, the bulimia nervosa market is segmented into oral, intravenous, and others. The bulimia nervosa market, by end user, has been segmented into hospitals & clinics, home care settings, specialty centers, and others. 

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The bulimia nervosa market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada. The European bulimia nervosa market has been segmented into Western Europe and Eastern Europe. The market in Western Europe has further been classified as France, Germany, Spain, the UK, Italy, and the rest of Western Europe.  The bulimia nervosa market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The Middle East & Africa bulimia nervosa market is segmented into the Middle East and Africa.    

Bulimia Nervosa Market Key Players

• Allergan


• Inc. (Ireland)


• Eli Lilly and Company (US)


• AstraZeneca (UK)


• Bristol-Myers Squibb Company (US)


• GlaxoSmithKline plc (UK)


• Pfizer Inc. (US)


• Johnson & Johnson Services


• Inc. (US)


• Dr. Reddy’s Laboratories Limited (India)


• Lupin Pharmaceuticals, Inc. (India)


• Aurobindo Pharma (India)


• Zydus Cadila (India)


• Apotex Inc. (Canada)


• Teva Pharmaceutical Industries Ltd (Israel)


• Sun Pharmaceutical Industries Ltd (India)

 Bulimia Nervosa Market Share (%), by Region, 2018